The latest price target for Biogen (NASDAQ:BIIB) was reported by Morgan Stanley on June 18, 2026. The analyst firm set a price target for $224.00 expecting BIIB to rise to within 12 months (a possible 14.02% upside). 62 analyst firms have reported ratings in the last year.

The latest analyst rating for Biogen (NASDAQ:BIIB) was provided by Morgan Stanley, and Biogen maintained their equal-weight rating.

The last upgrade for Biogen Inc happened on June 8, 2026 when Needham raised their price target to $255. Needham previously had a hold for Biogen Inc.

The last downgrade for Biogen Inc happened on December 10, 2025 when HSBC changed their price target from $144 to $143 for Biogen Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biogen was filed on June 18, 2026 so you should expect the next rating to be made available sometime around June 18, 2027.

While ratings are subjective and will change, the latest Biogen (BIIB) rating was a maintained with a price target of $206.00 to $224.00. The current price Biogen (BIIB) is trading at is $196.46, which is out of the analyst’s predicted range.